Evidence map›Paper›PMID 40109857›Full record

ReviewOncology research2025

Oncogenic and tumor-suppressive roles of Lipocalin 2 (LCN2) in tumor progression.

Baoxing Huang, Zichang Jia, Chenchen Fu, Moxian Chen, Zezhuo Su, Yunsheng Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. A Single-Cell Atlas of Uterine Carcinosarcoma from Diverse Ancestries.bioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Baoxing HuangClinical Laboratory, Shenzhen Children's Hospital, Shenzhen, 518038, China.
Zichang JiaClinical Laboratory, Shenzhen Children's Hospital, Shenzhen, 518038, China.
Chenchen FuState Key Laboratory of Tree Genetics and Breeding, Co-Innovation Center for Sustainable Forestry in Southern China, Key Laboratory of Tree Genetics and Biotechnology of Educational Department of China, Key Laboratory of State Forestry and Grassland Administration on Subtropical Forest Biodiversity Conservation, College of Life Sciences, Nanjing Forestry University, Nanjing, 210037, China.
Moxian ChenState Key Laboratory of Tree Genetics and Breeding, Co-Innovation Center for Sustainable Forestry in Southern China, Key Laboratory of Tree Genetics and Biotechnology of Educational Department of China, Key Laboratory of State Forestry and Grassland Administration on Subtropical Forest Biodiversity Conservation, College of Life Sciences, Nanjing Forestry University, Nanjing, 210037, China.
Zezhuo SuDepartment of Orthopaedics and Traumatology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Yunsheng ChenClinical Laboratory, Shenzhen Children's Hospital, Shenzhen, 518038, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipocalin-2 (LCN2) is a member of the lipocalin superfamily with multiple functions and can participate in the transport of a variety of small lipophilic ligands

Indexed as

Lipocalin-2NeoplasmsAnimalsBiomarkers, TumorCarcinogenesisCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticHumansBiomarkers, TumorLCN2 protein, humanLipocalin-2Gene regulationLipocalin 2 (LCN2)OncogenesisTumor progression

Identifiers

PMID40109857
PMCPMC11915076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.